The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo

AMN107 is a small molecule tyrosine kinase inhibitor developed, in the first instance, as a potent inhibitor of breakpoint cluster region-abelson (BCR-ABL). We tested its effectiveness against fusion tyrosine kinases TEL-platelet-derived growth factor receptorbeta (TEL-PDGFRbeta) and FIP1-like-1 (FI...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2005-11, Vol.106 (9), p.3206-3213
Hauptverfasser:	Stover, Elizabeth H, Chen, Jing, Lee, Benjamin H, Cools, Jan, McDowell, Elizabeth, Adelsperger, Jennifer, Cullen, Dana, Coburn, Allison, Moore, Sandra A, Okabe, Rachel, Fabbro, Doriano, Manley, Paul W, Griffin, James D, Gilliland, D Gary
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Bone Marrow Transplantation Cell Line Disease Models, Animal Humans Mice mRNA Cleavage and Polyadenylation Factors - antagonists & inhibitors mRNA Cleavage and Polyadenylation Factors - genetics mRNA Cleavage and Polyadenylation Factors - metabolism Mutation - genetics Myeloproliferative Disorders - metabolism Myeloproliferative Disorders - pathology Oncogene Proteins, Fusion - antagonists & inhibitors Oncogene Proteins, Fusion - genetics Oncogene Proteins, Fusion - metabolism Protein Kinase Inhibitors - pharmacology Pyrimidines - pharmacology Receptor, Platelet-Derived Growth Factor alpha - antagonists & inhibitors Receptor, Platelet-Derived Growth Factor alpha - genetics Receptor, Platelet-Derived Growth Factor alpha - metabolism Survival Rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!